11-Ketotigogenin cellobioside (pamaqueside): A potent cholesterol absorption inhibitor in the hamster

Journal of Medicinal Chemistry

Volumn 39, Issue 10, 1996, Pages

  McCarthy, Peter A ^a   DeNinno, Michael P ^a   Morehouse, Lee A ^a   Chandler, Charles E ^a   Bangerter, Faan Wen ^a   Wilson, Theresa C ^a   Urban, Frank J ^a   Walinsky, Stanley W ^a   Cosgrove, Patricia G ^a   Duplantier, Kimberly ^a   Etienne, John B ^a   Fowler, Michael A ^a   Lambert, John F ^a   O'Donnell, John P ^a   Pezzullo, Susan L ^a   Watson Jr , Harry A ^a   Wilkins, Robert W ^a   Zaccaro, Lawrence M ^a   Zawistoski, Michael P ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 KETOTIGOGENIN CELLOBIOSIDE; CHOLESTEROL; CP 148623; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PAMAQUESIDE; PRAVASTATIN; SAPONIN; SIMVASTATIN; TIQUESIDE; UNCLASSIFIED DRUG;

ALFALFA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; HAMSTER; HEART INFARCTION; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION;

ANIMALS; ANTILIPEMIC AGENTS; CARBOHYDRATE SEQUENCE; CHOLESTEROL, DIETARY; CRICETINAE; MOLECULAR SEQUENCE DATA; SAPONINS;

EID: 0029897260     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Potmesil, M. Camptothecins: From Bench Research to Hospital Wards. Cancer Res. 1994, 54, 1431-1439.
2. (a) Rao Vishnuvajjala, B.; Garzon-Aburbeh, A. Water Soluble Prodrugs of Camptothecin. U.S. Patent 4,943,579,1990.
3. (b) Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P. and Besterman, J. M. Plant Antitumor Agents. 30. Synthesis and Structure Activity of Novel Camptothecin Analogs. J. Med. Chem. 1993, 36, 2689-2700.
4. 4,5 we prefer the use of transport form in this case as it describes the performance of the PEG-camptothecin conjugate more accurately.
5. Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J. and Martinez, A., Drug Delivery Systems: Water Soluble Taxol-2′-Poly(ethylene glycol) Ester Prodrugs-Design and In Vivo Effectiveness. J. Med. Chem. 1996, 39, 424-431.
6. Bundgaard, H. Bioreversible Derivatization of Peptides. Delivery Systems for Peptide Drugs, Edited by Davis, S. S.; Ilium, L.; Tomlinson, E. Plenum Press: New York, 1986; pp 49-68.
7. 4
8. Cures are defined as survival for ≥ 40 days.
9. Luzzio, M. J.; Besterman, J. M.; Emerson, D. L.; Evans, M. G.; Lackey, K.; Leitner, P. L.; McIntyre, G.; Morton, B.; Myers, P. L.; Peel, M.; Sisco, J. M.; Sternbach, D. D.; Tong, W. Q.; Truesdale, A.; Uehling, D. E.; Vuong, A. and Yates, J. Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase. J. Med. Chem. 1995, 38, 395-401.
10. (a) Wall, M. E.; Wani, M. C. Camptothecin and Taxol: Discovery to Clinic-Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995, 55, 753-760.
11. (b) Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. Structure Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for a Specific Receptor Site and a Relation to Tumor Activity. Ibid. 1989, 49, 1465-1469.
12. (c) Hertzberg, R. P.; Caranfa, M.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S.-H.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. Modification of the Hydroxy Lactone Ring of Camptothecin: Inhibition of Mammalian Topoisomerase I and Biological Activity. J. Med. Chem. 1989, 32, 715-720.
13. Burke, T. G.; Mi, Z. The Structural Basis of Camptothecin Interactions with Serum Albumin: Impact on Drug Stability. J. Med. Chem. 1994, 37, 40-46.
14. Mi, Z.; Burke, T. G. Differential Interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components. Biochemistry 1994, 33, 10325-10336.
15. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin a Novel Alkaloidal Leukemia and Tumor Inhibitor from "Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
16. 1 is known to undergo lactone ring opening to a much greater extent in human plasma than in other species, and HSA has been suggested as the plasma component responsible for promoting this rapid and extensive hydrolysis (Mi, Z; Burke, T. G. Marked Interspecies Variations Concerning the Interactions of Camptothecin with Serum Albumins: A Frequency - Domain Fluorescence Spectroscopic Study. Biochemistry 1994, 33, 12540-12545).